<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>13</volume><submitter>Wei W</submitter><pubmed_abstract>Antimicrobial resistance (AMR) represents one of the main challenges in Tuberculosis (TB) treatment. Investigating the genes involved in AMR and the underlying mechanisms holds promise for developing alternative treatment strategies. The results indicate that dehydroquinate synthase (DHQS) regulates the susceptibility of &lt;i>Mycobacterium bovis&lt;/i> BCG to first-line anti-TB drug streptomycin. Perturbation of the expression of &lt;i>aroB&lt;/i> encoding DHQS affects the susceptibility of &lt;i>M. bovis&lt;/i> BCG to streptomycin. Purified DHQS impairs &lt;i>in vitro&lt;/i> antibacterial activity of streptomycin, but did not hydrolyze or modify streptomycin. DHQS directly binds to streptomycin while retaining its own catalytic activity. Computationally modeled structure analysis of DHQS-streptomycin complex re</pubmed_abstract><journal>Frontiers in microbiology</journal><pagination>818881</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9063660</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Dehydroquinate Synthase Directly Binds to Streptomycin and Regulates Susceptibility of &lt;i>Mycobacterium bovis&lt;/i> to Streptomycin in a Non-canonical Mode.</pubmed_title><pmcid>PMC9063660</pmcid><pubmed_authors>He J</pubmed_authors><pubmed_authors>Chen M</pubmed_authors><pubmed_authors>Jiang X</pubmed_authors><pubmed_authors>Hu X</pubmed_authors><pubmed_authors>Yang M</pubmed_authors><pubmed_authors>Cai L</pubmed_authors><pubmed_authors>Wei W</pubmed_authors><pubmed_authors>Qiao J</pubmed_authors><pubmed_authors>Cui T</pubmed_authors></additional><is_claimable>false</is_claimable><name>Dehydroquinate Synthase Directly Binds to Streptomycin and Regulates Susceptibility of &lt;i>Mycobacterium bovis&lt;/i> to Streptomycin in a Non-canonical Mode.</name><description>Antimicrobial resistance (AMR) represents one of the main challenges in Tuberculosis (TB) treatment. Investigating the genes involved in AMR and the underlying mechanisms holds promise for developing alternative treatment strategies. The results indicate that dehydroquinate synthase (DHQS) regulates the susceptibility of &lt;i>Mycobacterium bovis&lt;/i> BCG to first-line anti-TB drug streptomycin. Perturbation of the expression of &lt;i>aroB&lt;/i> encoding DHQS affects the susceptibility of &lt;i>M. bovis&lt;/i> BCG to streptomycin. Purified DHQS impairs &lt;i>in vitro&lt;/i> antibacterial activity of streptomycin, but did not hydrolyze or modify streptomycin. DHQS directly binds to streptomycin while retaining its own catalytic activity. Computationally modeled structure analysis of DHQS-streptomycin complex re</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022</publication><modification>2026-03-12T21:05:02.234Z</modification><creation>2025-04-25T18:03:25.102Z</creation></dates><accession>S-EPMC9063660</accession><cross_references><pubmed>35516432</pubmed><doi>10.3389/fmicb.2022.818881</doi></cross_references></HashMap>